Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus and Human Parainfluenza Virus Type 3 Vaccine, When Administered to Healthy Adults
Sponsor: ModernaTX, Inc.
A PHASE1 clinical study on Human Metapneumovirus and Human Parainfluenza Infection, this trial is completed. The trial is conducted by ModernaTX, Inc. and has accumulated 8 data snapshots since 2017. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jan 2020 — Mar 2020 [monthly]
Active Not Recruiting PHASE1
▶ Show 3 earlier versions
-
Feb 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE1
-
Aug 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2018 — Aug 2018 [monthly]
Recruiting PHASE1
First recorded
Dec 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ModernaTX, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .